← Back to Search

mRNA Therapy

mRNA-3927 for Propionic Acidemia

Phase 1 & 2
Recruiting
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must not have
History of liver and/or kidney transplant.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the long-term safety of a medication for propionic acidemia, a rare metabolic disorder.

Who is the study for?
This trial is for individuals with propionic acidemia who were previously in the mRNA-3927-P101 study. They must have completed that study's end-of-treatment visit within 10 days of starting this one. People can't join if they've had a liver or kidney transplant, aren't expected to benefit from more treatment, or have health issues that make it risky.
What is being tested?
The trial is testing the long-term safety and effectiveness of a drug called mRNA-3927 in patients with propionic acidemia who took part in an earlier phase of research. It continues where the previous study left off.
What are the potential side effects?
Since this is an extension study for mRNA-3927, side effects are monitored over a longer period but may include reactions related to immune response, potential organ stress, and other unforeseen issues as observed during ongoing surveillance.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a liver or kidney transplant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: mRNA-3927Experimental Treatment1 Intervention
Participants will receive the applicable dose identified during Study mRNA-3927-P101 (NCT04159103) on Day 1. The dose can be adjusted based on Sponsor recommendation.

Find a Location

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor
116 Previous Clinical Trials
61,467,425 Total Patients Enrolled
3 Trials studying Propionic Acidemia
365 Patients Enrolled for Propionic Acidemia

Media Library

mRNA-3927 (mRNA Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05130437 — Phase 1 & 2
Propionic Acidemia Research Study Groups: mRNA-3927
Propionic Acidemia Clinical Trial 2023: mRNA-3927 Highlights & Side Effects. Trial Name: NCT05130437 — Phase 1 & 2
mRNA-3927 (mRNA Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05130437 — Phase 1 & 2
~23 spots leftby Dec 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top